Ocugen, Inc. receives European Medicines Agency ATMP designation for new gene therapy

Retrieved on: 2025-02-03 19:44:31

Tags for this article:

Click the tags to see associated articles and topics

Ocugen, Inc. receives European Medicines Agency ATMP designation for new gene therapy. View article details on hiswai:

Excerpt

OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication.

Article found on: europe.ophthalmologytimes.com